Associated Papers
Confounding Effect of Hepatic Carboxylesterase 1 (CES1) Variability on Clopidogrel Oxidation.
Subash S et al.
Molecular Pharmaceutics, 2025
Increased Plasma Concentrations of 6-oxo-Methylphenidate in CES1 G134E Carriers Following a Single Oral Dose of Methylphenidate.
Zhang Q et al.
Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents, 2025
Structural equation modelling of nucleotide polymorphisms and pharmacokinetics in direct oral anticoagulant use for stroke and embolism prevention in atrial fibrillation.
Pham TP et al.
European Journal of Pharmacology, 2025
A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications.
Shorbaji A et al.
Npj Genomic Medicine, 2025
Exploring the Role of Genetic and Genomic Factors in Therapeutic Response to Heart Failure: A Comprehensive Analytical Review.
Ferro A et al.
Genes, 2025
Pharmacogenetic Testing for Predicting Methylphenidate Treatment Outcomes in Childhood Attention Deficit Hyperactivity Disorder in Turkey: Focus on Carboxylesterase 1, Latrophilin-3, and Catechol-O-Methyltransferase.
Suzer Gamli I et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics, 2025
Impact of genetic polymorphisms and drug-drug interactions mediated by carboxylesterase 1 on remimazolam deactivation.
Wang Z et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2025
Randomized evaluation of the loss-of-function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics.
Lewis JP et al.
Clinical and Translational Science, 2024
Pharmacogenetic study of CES1 gene and enalapril efficacy.
Hussain M et al.
Journal of Applied Genetics, 2024
Discovery of a novel homocysteine thiolactone hydrolase and the catalytic activity of its natural variants.
Hou S et al.
Protein Science : a Publication of the Protein Society, 2024
Prediction of adverse drug reactions due to genetic predisposition using deep neural networks.
Dafniet B et al.
Molecular Informatics, 2024
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review.
Liu Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2024
Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients.
Cura Y et al.
Pharmaceutics, 2023
CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel.
Ramste M et al.
Clinical and Translational Science, 2023
Pharmacogenetics of Antiplatelet Therapy.
Castrichini M et al.
Annual Review of Pharmacology and Toxicology, 2023
Identification of regulatory variants of carboxylesterase 1 (CES1): A proof-of-concept study for the application of the Allele-Specific Protein Expression (ASPE) assay in identifying cis-acting regulatory genetic polymorphisms.
Her L et al.
Proteomics, 2023
The Influence of Structural Variants of the CES1 Gene on the Pharmacokinetics of Enalapril, Presumably Due to Linkage Disequilibrium with the Intronic rs2244613.
Ikonnikova A et al.
Genes, 2022
In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir.
Zhang Q et al.
Chemico-biological Interactions, 2022
Physiologically-Based Pharmacokinetic Modeling to Predict Methylphenidate Exposure Affected by Interplay Among Carboxylesterase 1 Pharmacogenetics, Drug-Drug Interactions, and Sex.
Xiao J et al.
Journal of Pharmaceutical Sciences, 2022
The Influence of the CES1 Genotype on the Pharmacokinetics of Enalapril in Patients with Arterial Hypertension.
Ikonnikova A et al.
Journal of Personalized Medicine, 2022
Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C.
Loucks CM et al.
Liver International : Official Journal of the International Association for the Study of the Liver, 2022
Contributions of Cathepsin A and Carboxylesterase 1 to the Hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis.
Li J et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2022
Association between CES1 rs2244613 and the pharmacokinetics and safety of dabigatran: Meta-analysis and quantitative trait loci analysis.
Li H et al.
Frontiers in Cardiovascular Medicine, 2022
Associations between CES1 variants and dosing and adverse effects in children taking methylphenidate.
Brown JT et al.
Frontiers in Pediatrics, 2022
The Utility of Pharmacogenetics Testing in Psychiatric Populations.
Jürgens G
Journal of Personalized Medicine, 2021
Effect of CES1 genetic variation on enalapril steady-state pharmacokinetics and pharmacodynamics in healthy subjects.
Her LH et al.
British Journal of Clinical Pharmacology, 2021
Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers.
Wang X et al.
Clinical and Translational Science, 2021
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.
Badary OA
The Pharmacogenomics Journal, 2021
Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.
Fricke-Galindo I et al.
Viruses, 2021
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium.
Verma SS et al.
Clinical Pharmacology and Therapeutics, 2020
The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting.
Stenson PD et al.
Human Genetics, 2020
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
Lewis JP et al.
European Heart Journal. Cardiovascular Pharmacotherapy, 2020
Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.
Her L et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2020
The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin.
Qian Y et al.
Chemico-biological Interactions, 2020
Is genetic variability in carboxylesterase-1 and carboxylesterase-2 drug metabolism an important component of personalized medicine?
Laizure SC et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
Liu S et al.
Frontiers in Pharmacology, 2020
The impact of human CES1 genetic variation on enzyme activity assessed by ritalinic acid/methylphenidate ratios.
Stage C et al.
Basic & Clinical Pharmacology & Toxicology, 2019
Influences of an NR1I2 polymorphism on heterogeneous antiplatelet reactivity responses to clopidogrel and clinical outcomes in acute ischemic stroke patients.
Chen YB et al.
Acta Pharmacologica Sinica, 2019
Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation.
Kampouraki E et al.
Expert Opinion on Drug Metabolism & Toxicology, 2019
Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.
Saiz-Rodríguez M et al.
Clinical Therapeutics, 2019
CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel.
Holmberg MT et al.
Clinical Pharmacology and Therapeutics, 2019
Functional Study of Carboxylesterase 1 Protein Isoforms.
Wang X et al.
Proteomics, 2019
Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants.
Kanuri SH et al.
Journal of Personalized Medicine, 2019
Cytochrome P450 genotype-guided drug therapies: An update on current states.
Dong AN et al.
Clinical and Experimental Pharmacology & Physiology, 2018
Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD.
Myer NM et al.
Molecular Psychiatry, 2018
Genetic variation in human carboxylesterase CES1 confers resistance to hepatic steatosis.
Lian J et al.
Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids, 2018